City of Hope

We recently spoke with Tycel Phillips, MD, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, about his team’s interim analysis of their dose-escalation study of glofitamab against relapsed/refractory B-cell non-Hodgkin lymphoma.

In the final part of our interview with Joseph Mikhael, MD, MEd, FRCPC, FACP, he addresses how patients who experience an early relapse of their multiple myeloma are predisposed to worse outcomes.

In this interview from our coverage of the European Hematology Association 2024 Congress, Joseph Mikhael, MD, MEd, FRCPC, FACP, International Myeloma Foundation, discusses the complex principles that underlie treating multiple myeloma (MM) in the US.

Within the GAIN-S model, geriatric care assessments among older patients with cancer are combined with care interventions, and it is delivered soon before patients have an intervention on their cancer therapy, says William Dale, MD, PhD, FASCO, City of Hope.

Glofitamab is currently being investigated in a phase 1/2, multicenter, open-label, dose-escalation study as monotherapy and in combination with obinutuzumab, following 1-time fixed-dose pretreatment with obinutuzumab for B-cell non-Hodgkin lymphoma, of which mantle cell lymphoma (MCL) is a rare type.

Clinical use of liquid biopsies to determine the likelihood of CRC is the goal based on its effectiveness in recent studies.

MicroRNAs could be a key to future testing for colorectal cancer (CRC) and determining treatment.

Ajay Goel, PhD, AGAF, discusses study findings that could help in earlier detection of lymph node metastases and colorectal cancer (CRC).

Ajay Goel, PhD, AGAF, explains the significance of 2 new studies that found that early-onset colorectal cancer (EOCRC) and recurrence in CRC could both be predicted using new blood and tissue tests.

The approval fills a void for patients with CLL or SLL whose disease progresses after treatment with a BTK inhibitor and a BCL-2 inhibitor; until now, there has been no standard of care.

Coverage from the discussion, "Cancer Genomics: The Gateway to Access and Health Equity” on the first day of Patient-Centered Oncology Care 2023.

Abstracts from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition provided new insight into multiple treatments for patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and follicular lymphoma (FL).

Findings from PREVENT-HF put to rest the idea that once remodeling in the heart's structure starts following anthracyclines that nothing can be done to treat it.

Articles highlighting links between COVID-19 and cancer were among the most-read in Evidence-Based Oncology™ in 2023.

In AUGMENT-101, patients with R/R KMT2Ar acute leukemia had high overall response rates; despite being heavily pretreated, 40% were able to proceed to transplant and the KMT2Ar cohort was stopped early.

A minimally invasive procedure could revolutionize breast surgery; Black women experience the worst birthing outcomes; Kaiser Permanente health workers' concerns over labor disputes persist.

In an interview with Targeted Oncology, Sagun Shrestha, MD, evaluated new developments and clinical trials for patients with extensive-stage small cell lung cancer.

The landmark trial harmonized treatment between adult and pediatric patients with classic Hodgkin lymphoma, who historically have received different chemotherapy regimens; young patients have received more treatment with radiation.

CMS in February 2023 announced 3 new models for testing by the Center for Medicare & Medicaid Innovation—all of which “aim to lower the cost of drugs, promote accessibility to life-changing drug therapies, and improve quality of care.”